Infant Bacterial Therapeutics AB

Operational Progress

• Continued constructive dialogue with the U.S. Food and Drug Administration (FDA) regarding IBP-9414.
• Received a letter from the FDA on May 1, 2026, indicating that IBP-9414 study results, combined with other scientific information, could be considered sufficient for market approval submission without a post-marketing study.
• Analytical work for…